Huons Unveils Promising Preclinical Results for Crohn's Disease Fibrosis Drug Candidate
Predicted impact: Low
Preclinical drug results with no clinical or revenue milestone.
Huons휴온스
243070 · KOSDAQ · ₩243070 · 휴온스
₩17,190▲ ₩340 (2.02%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −43.45%
- Market cap
- ₩206B
- Enterprise value
- ₩314B
- P/E
- 10.9×
- P/B
- 0.6×
- Dividend yield
- 5.4%
- ROE
- 5.1%
- Net margin
- 3.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.6% from the high
₩16,840Today: ₩16,970 – ₩17,500₩41,500
Returns
- 1W−4.0%
- 1M−8.7%
- 3M−30.7%
- 6M−35.6%
- YTD−37.3%
- 1Y−43.5%
- Volume today
- 17,440
- 0.8× the 20-day average
- Traded today
- ₩298M
- Listed shares
- 11,979,665
- EPS (12 months)
- ₩1,575
- Earnings yield 9.2%
AI research · Update noteHuons: Model Fair Value Estimate Cut to ₩51,504 Base Case as Discount Rate Edges Lower and Bear Case Falls SharplyThe evidence points to a weaker and less certain valuation picture than in the previous report.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.3% over the last month; the price is below its 20-day average.
- News impactLow7 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Huons stock overview
Huons (휴온스, KRX: 243070) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩17,190 on Oct 27, 2026, up 2.02% on the day, giving it a market value of ₩206B.
Key facts
- Market cap
- ₩206B
- Sector
- Biotech & Pharma
- Latest price change
- +2.02%
- As of
- Oct 27, 2026
- Main business
- , Ltd.
Quick answers about Huons
- What does Huons do?
- , Ltd. is a Korean pharmaceutical company founded in 1965 that manufactures and sells prescription drugs, beauty and wellness products such as vitamin injections and weight-loss medicines, and contract manufactures drugs for major domestic and foreign pharmaceutical companies. Its products are supplied to hospitals, clinics and pharmacies in Korea, and some injectable products are exported to the United States under FDA approval.
- What is the market cap of Huons?
- The market capitalisation of Huons was ₩206B at the close on Oct 27, 2026.
- Who are the largest shareholders of Huons?
- According to the latest official filings, the largest reported holders are Huons Global (44.82%, as of Mar 25, 2026); Fidelity Management & Research Company LLC (9.99%, as of Feb 19, 2025); Fidelity Low-Priced Stock Fund (7.13%, as of Jul 31, 2026).
- When is the next earnings report from Huons?
- Korean companies rarely announce results dates in advance. Based on when Huons filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Huons?
- Yes. The National Pension Service held 0.71% of Huons shares as of Dec 31, 2025.
Company profile
Hugon Co., Ltd. is a Korean pharmaceutical company founded in 1965 that manufactures and sells prescription drugs, beauty and wellness products such as vitamin injections and weight-loss medicines, and contract manufactures drugs for major domestic and foreign pharmaceutical companies. Its products are supplied to hospitals, clinics and pharmacies in Korea, and some injectable products are exported to the United States under FDA approval. The company operates GMP-certified production plants in Chungbuk, and its subsidiaries include a health functional food business and a finished-drug manufacturer.
Written by AI from the company's latest annual report.
- Korean name
- 휴온스
- Sector
- Biotech & Pharma
- CEO
- Song Soo-young
- Founded
- May 2016
- Listed
- Jun 2016
- Listed shares
- 11,979,665
- Fiscal year ends
- Month 12
- Website
- www.huons.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Huons completes preclinical trial showing intestinal fibrosis inhibition effect for Crohn's disease new drug
Predicted impact: Low
Preclinical Crohn's result already reported in recent items; early-stage research only.
Huons Presents Non-clinical Results of Fibrostenotic Crohn's Disease Treatment Candidate in Poster at European Digestive Disease Meeting
Predicted impact: Low
Conference poster on preclinical results; early-stage with no financial size.
Recent filings
See all- Not Designated as Unfaithful Disclosure Company (Designation Deferred)Oct 21, 2026
- Notice of Designation as Unfaithful Disclosure Entity (Two Cases of Disclosure Reversal)Sep 23, 2026
- Merger decisionAug 26, 2026
- Amended: Shareholders' meeting calledAug 26, 2026
- Amended: Merger decisionAug 26, 2026
Titles in Korean until English translations are added.
Also known as: Huons / 휴온스 / 243070 / KRX:243070
Source: KRX statistical information